Effect of Vitamin D3 on Cardiovascular Risk Factors
Primary Purpose
Hypertensive Disease, Deficiency of Vitamin D3
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Vitamin D3
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Hypertensive Disease
Eligibility Criteria
Inclusion Criteria:
- human volunteers with mild hypertension
Exclusion Criteria:
- use of antihypertensive medication
- use of vitamin d or calcium supplements
- known renal, inflammatory or malignant diseases
- hypercalcemia or hypercalciuria
- participation in other clinical studies
- use of tanning booths during the study
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
vitamin d
Placebo
Arm Description
Outcomes
Primary Outcome Measures
blood pressure
major outcome variable is the decrease oy systolic blood pressure in the treatment group in comparison with the placebo group.
Secondary Outcome Measures
Full Information
NCT ID
NCT01501916
First Posted
November 4, 2011
Last Updated
October 10, 2018
Sponsor
Martin-Luther-Universität Halle-Wittenberg
Collaborators
German Federal Ministry of Education and Research
1. Study Identification
Unique Protocol Identification Number
NCT01501916
Brief Title
Effect of Vitamin D3 on Cardiovascular Risk Factors
Official Title
Effect of Vitamin D3 on Cardiovascular Risk Factors: a Randomized Trial in Human
Study Type
Interventional
2. Study Status
Record Verification Date
October 2018
Overall Recruitment Status
Completed
Study Start Date
December 2012 (undefined)
Primary Completion Date
April 2013 (Actual)
Study Completion Date
December 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Martin-Luther-Universität Halle-Wittenberg
Collaborators
German Federal Ministry of Education and Research
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The aim of this study is to investigate whether a supplementation of Vitamin D3 can be used to reduce atherosclerotic risk factors.
Detailed Description
It is the objective of this study to investigate whether a supplementation with Vitamin D3 can be used to reduce atherosclerotic risk factors such as hypertension, inflammation and hyperlipidemia. The research question is whether Vitamin D3 can lower blood pressure in mildly hypertensive subjects who are naive to antihypertensive medication, whether Vitamin D reduces the level of systemic inflammation and whether Vitamin D3 has an effect on blood lipids.
major outcomes:
- decrease of systolic blood pressure in the treatment group in comparison with the placebo group
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertensive Disease, Deficiency of Vitamin D3
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
250 (Actual)
8. Arms, Groups, and Interventions
Arm Title
vitamin d
Arm Type
Experimental
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Dietary Supplement
Intervention Name(s)
Vitamin D3
Other Intervention Name(s)
cholecalciferol
Intervention Description
daily dosage of 50 µg Vitamin D3 for 8 weeks
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Intervention Description
daily intake of placebo
Primary Outcome Measure Information:
Title
blood pressure
Description
major outcome variable is the decrease oy systolic blood pressure in the treatment group in comparison with the placebo group.
Time Frame
after 8 weeks of supplementation
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
human volunteers with mild hypertension
Exclusion Criteria:
use of antihypertensive medication
use of vitamin d or calcium supplements
known renal, inflammatory or malignant diseases
hypercalcemia or hypercalciuria
participation in other clinical studies
use of tanning booths during the study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jutta Dierkes, Prof. Dr.
Organizational Affiliation
Institut für Agrar- und Ernährungswissenschaften
Official's Role
Study Director
12. IPD Sharing Statement
Learn more about this trial
Effect of Vitamin D3 on Cardiovascular Risk Factors
We'll reach out to this number within 24 hrs